RECOMBINANT INTERLEUKIN 2 INDUCES PROLIFERATION AND DIFFERENTIATION OF HUMAN B LYMPHOCYTES

Author(s):  
Juha Punnonen ◽  
Jussi Eskola
2021 ◽  
pp. 11-18
Author(s):  
O.A. Gizinger

The article shows the scheme of complex therapy of bacterial meningitis using the recombinant cytokine interleukin 2. The clinical, immunological and microbiological efficacy of the use of recombinant interleukin 2 in the complex therapy of bacterial meningitis is shown. The biological effects of recombinant IL-2 justify its use in the complex therapy of meningitis due to its influence on the activity of metabolic processes at the cellular and subcellular levels, the ability to stabilize the system of lipid peroxidation of cell membranes, to influence the processes of clonal proliferation and differentiation of T- and B-lymphocytes improving the quality of the therapy.


2022 ◽  
pp. 28-33
Author(s):  
Oksana Anatolievna Gizinger ◽  
◽  
Irina Yurievna Lepina ◽  
Marina Nikolaevna Bagdasaryan ◽  
◽  
...  

The article analyzes the pathogenetic features of bacterial meningitis and substantiates the scheme of complex therapy of the disease using the recombinant cytokine interleukin-2 (IL2). The clinical, immunological and microbiological efficacy of the complex therapy scheme has been revealed. It has been shown that the pleiotropic effects of recombinant IL-2, its effect on the activity of metabolic processes at the cellular and subcellular levels, the ability to stabilize the system of lipid peroxidation of cell membranes, the ability to influence the processes of clonal proliferation and differentiation of T- and B-lymphocytes, make its use justified in complex therapy of meningitis.


1984 ◽  
Vol 30 (9) ◽  
pp. 1539-1545 ◽  
Author(s):  
N M Kouttab ◽  
S Mehta ◽  
J Morgan ◽  
N Tannir ◽  
C Sahasrabuddhe ◽  
...  

Abstract The development of a competent immunoregulatory response in the face of an antigenic challenge is modulated by soluble proteins of relatively low molecular mass. Lymphokines and monokines, secreted by cells of T lineage and cells of the monocyte/microphage series, respectively, function in a bimodal amplification network that results in the proliferation and differentiation of the immunoregulatory cells. Interleukin 1 is typically assayed by its effect on thymocytes or by its ability to promote the T cell-dependent release of interleukin 2. Interleukin 2 is routinely measured by its ability to support the long-term growth of cultured T cells, whereas B cell growth factor is measured by its ability to support the long-term growth of cultured B lymphocytes. The availability of homogeneous purified factors and the subsequent availability of monoclonal antibodies against these reagents should allow for the development of rapid quantitative assays for these analytes in diverse biological fluids. In addition, large quantities of purified reagents will promote studies to determine therapeutic efficacy in several immunodeficiency syndromes.


1992 ◽  
Vol 5 (3) ◽  
pp. 155-163 ◽  
Author(s):  
B. Dugas ◽  
J.P. Kolb ◽  
Nathalie Paul-Eugene ◽  
J.M. Mencia-Huerta ◽  
P. Braquet

The role of the platelet activating factor in human B lymphocyte responses to Interleukin-2 was examined and compared with that of Interleukin-4 by assessing the ability of this molecule to modulate proliferation and differentiation. Highly purified B lymphocytes were prestimulated for 48 h with Staphylococcus aureus Cowan Strain I and then were cultured with Interleukin-2 alone or in combination with either Interleukin-4 or the platelet activating factor and the proliferation (after 3 days) and the immunoglobulins (IgG and IgM) production (after 7 days) were evaluated. When SAC-activated B lymphocytes were preincubated overnight with PAF (0.0001 to 1 μM) or with IL-4 (1 to 100 U/ml) both the IL-2-induced proliferation and immunoglobulins secretion were inhibited. This inhibition was not a reflection of a decreased expression of the IL-2 receptor (CD25) because this expression was not modified on SAC-activated B lymphocytes after preincubation with either PAF or IL-4. Moreover, this suppression effect was not the result of a delayed response to IL-2. The PAF-induced suppression was overcome in the presence of PAF antagonists (BN 52021 and BN 50730) but was not modified in the presence of a neutralizing anti-IL-4 antiserum. On the other hand, the IL-4 mediated suppression was totally reversed in the presence of the neutralizing anti-serum and only marginally reversed in the presence of the PAF antagonists. These results indicate that both PAF and IL-4 may exert a number of immunoregulatory actions on human B lymphocyte proliferation and differentiation. They interfere with the stimulation of activated B lymphocytes by IL-2 and could play an important immunoregulatory role in the determination of isotypic regulation in the specific humoral responses.


2021 ◽  
pp. 11-18
Author(s):  
Margarita Valentinovna Antonenko

The article contains information presented in the open press based on the results of studies of the clinical efficacy of recombinant interleukin 2. Roncoleukin provides immune protection against tumor cells, pathogens of viral, bacterial and fungal nature, activates the processes of tissue repair and regeneration, promotes adequate interaction of the immune, endocrine and nervous systems. Interleukin-2 is an activation, proliferation and differentiation factor for T- and B-lymphocytes, T-regulatory cells, natural killer cells, monocytes / macrophages, dendritic and oligodendroglial cells; protects activated T cells from premature death (apoptosis) and cancels immunological tolerance.


Blood ◽  
1989 ◽  
Vol 74 (4) ◽  
pp. 1355-1359 ◽  
Author(s):  
MX Zhou ◽  
HW Jr Findley ◽  
AH Ragab

Abstract We are reporting here that low-mol wt B-cell growth factor (LMW-BCGF) and recombinant interleukin-2 (rIL-2) are together able to induce CD3+ cytotoxic T lymphocytes (CTL) with lymphokine-activated killer cell (LAK) activity from the bone marrow (BM) cells of children with acute lymphoblastic leukemia (ALL). Ficoll-Hypaque (FH)-separated BM cells were obtained from patients with active disease (at diagnosis N = 13, in relapse N = 15) and in complete remission (CR; N = 12). CD3+ cells were removed by Leu-4 antibody and immunobeads. Cells were cultured (10(5) cells/mL) in semisolid media with rIL-2 (100 mu/mL), LMW-BCGF (0.1 mu/mL), and the combination of rIL-2 plus LMW-BCGF, respectively, for seven to ten days. Pooled colonies were harvested for phenotyping. LMW-BCGF plus rIL-2 induced large numbers of CD3+ colonies from CD3- precursors. rIL-2 alone did not induce colony formation. In addition, cells were cultured in liquid media with LMW-BCGF, rIL-2, and the combination of LMW-BCGF plus rIL-2, respectively, for seven to 21 days. They were harvested for phenotyping, and cytotoxicity assays were performed v K562, Raji, and autologous leukemic cells. LMW-BCGF plus rIL-2 induced significant expansion of CD3+ cells from CD3- precursors, and these cells were activated to kill autologous leukemic cells in addition to Raji and K562 cell lines. LMW-BCGF or rIL-2 alone did not induce significant expansion or activation of cytotoxic CD3- cells. Our hypothesis is that LMW-BCGF plus rIL-2 stimulates the proliferation and activation of CD3- precursors from the BM cells of children with acute leukemia to become CD3+ cells that have LAK activity. This finding may have therapeutic implications.


Sign in / Sign up

Export Citation Format

Share Document